Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“Clearmind”) NASDAQ:CMND, a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder (“AUD”), addiction, and weight management, today announced the fili…